SHR-1816
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 21, 2025
Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=60 | Terminated | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | N=96 ➔ 60 | Not yet recruiting ➔ Terminated; Sponsor internal strategy change.
Enrollment change • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 15, 2022
Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=96 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
New P1 trial • Diabetes • Metabolic Disorders
1 to 2
Of
2
Go to page
1